At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 396 enrolled
Drug / intervention
Ara-C, Mitoxantrone, Daunorubicin, Thioguanindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia
In Brief
A Phase 3 clinical trial evaluating Ara-C, Mitoxantrone, Daunorubicin, Thioguanin for Acute Myeloid Leukemia. Completed, enrolled 396 participants across 32 sites.
Detailed Summary
Evaluation weather early chemotherapy attempts for remission induction can improve the results of patients with Acute Myeloid Leukemia (AML), as compared to the standard group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesGermany
CollaboratorsKompetenznetz Leukämien
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJun 2011
Primary CompletionAug 2012
Study CompletionJul 2017
TodayJul 2026
First PostedJun 27, 2011
Enrollment StartJul 1, 2009
Primary CompletionAug 1, 2012
Study CompletionJul 5, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.0 years ago
Interventions
Ara-C, Mitoxantrone, Daunorubicin, Thioguanindrug
Chemotherapy